Connecting Innovation to Purpose

Incretin analogs have transformed the field of obesity and its commercial value But... 28 Muscle loss Tolerability Accessibility → Long-term compliance is ~ 27% Sales (2018-2022) and sales estimates (2023-2028) for Ozempic, Wegovy, and Mounjaro reflect significant uptake and expectations Sales ($B) 25 20 15 10 5 0 2018 2019 2020 2021 2022 2023E 2024E 2025E 2026E 2027E 2028E Ozempic Wegovy Mounjaro Source(s): RBC report Oct 2023

View entire presentation